QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.076794v1 312/3/1298    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cao, Y.-J. Articles by Puttfarcken, P. S. Search for Related Content PubMed PubMed Citation Articles by Cao, Y.-J. Articles by Puttfarcken, P. S.

NEUROPHARMACOLOGY

Nicotinic Acetylcholine Receptor-Mediated [³H]Dopamine Release from Hippocampus

Neurological Diseases Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

The mechanism of nicotinic acetylcholine receptor (nAChR)-induced hippocampal dopamine (DA) release was investigated using rat hippocampal slices. nAChRs involved in hippocampal DA and norepinephrine (NE) release were investigated using prototypical agonists and antagonists and several relatively novel compounds: ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine], (±)-UB-165 [(2-chloro-5-pyridyl)-9-azabicyclo [4.2.1]non2-ene], and MG 624 [N,N,N-triethyl-2-[4-(2 phenylethenyl)phenoxy]-ethanaminium iodine]. (±)-Epibatidine, (±)-UB-165, anatoxin-a, ABT-594, (-)-nicotine, 1,1-dimethyl-4-phenyl-piperazinium iodide, and (-)-cytisine (in decreasing order of potency) evoked [³H]DA release in a mecamylamine-sensitive manner. Aside from (±)-UB-165, all the agonists displayed full efficacy relative to 100 µM (-)-nicotine in [³H]DA release. In contrast, (±)-UB-165 was a partial agonist, evoking 58% of 100 µM (-)-nicotine response. Mecamylamine, MG 624, hexamethonium, d-tubocurare, and dihydro--erythroidine (in decreasing order of potency), but not -conotoxin-MII, methyllycaconitine, -conotoxin-ImI, or -bungarotoxin, attenuated 100 µM (-)-nicotine-evoked [³H]DA release in a concentration-dependent manner. (±)-UB-165, ABT-594, and MG 624 exhibited different pharmacologic profiles in the [³H]NE release assay when compared with their effect on [³H]DA release. ABT-594 was 4.5-fold more potent, and (±)-UB-165 was a full agonist in contrast to its partial agonism in [³H]DA release. MG 624 potently and completely blocked NE release evoked by 100 µM (-)-nicotine and 10 µM (±)-UB-165, whereas it only partially inhibited (-)-nicotine-evoked [³H]DA release. In conclusion, we provide evidence that [³H]DA can be evoked from the hippocampus and that the pharmacologic profile for nAChR-evoked hippocampal [³H]DA release suggests the involvement of 34^* and at least one other nAChR subtype, thus distinguishing it from that of nAChR-evoked hippocampal [³H]NE release.

Address correspondence to: Dr. Pamela Puttfarcken, Neurological Diseases Research, Global Pharmaceutical Research and Development, 100 Abbott Park Road, Building AP9A, Room 324, Abbott Park, IL 60064-6125. E-mail: pamela.puttfarcken{at}abbott.com

This article has been cited by other articles:

				J. Barik and S. Wonnacott Indirect Modulation by {alpha}7 Nicotinic Acetylcholine Receptors of Noradrenaline Release in Rat Hippocampal Slices: Interaction with Glutamate and GABA Systems and Effect of Nicotine Withdrawal Mol. Pharmacol., February 1, 2006; 69(2): 618 - 628. [Abstract] [Full Text] [PDF]